Whole genome sequencing of liquid biopsies to predict doxorubicin response in ovarian cancer

“精准肿瘤学”正在开发新的肿瘤DNA基因测试，以消除治疗最致命癌症的猜测。我们使用机器学习来发现肿瘤DNA的模式，这些模式可以用来预测一个人对癌症药物的反应。我们目前的测试方法是对患者的肿瘤进行活组织检查，以预测他们对治疗卵巢癌的药物是否有反应。在这个项目中，我们想看看我们是否可以在病人的血液样本上使用相同的测试，而不是组织样本。如果成功，这将减少患者的创伤，更安全，更方便，并将降低测试的成本。

Pinpoint Oncology is developing new genetic tests on DNA from tumours to take the guesswork out of treating the deadliest cancers. We use machine learning to find patterns in tumour DNA which can be used to predict a person's response to cancer drugs.Our current test uses a biopsy of a patient's tumour to predict if they will respond to a drug used to treat ovarian cancer. In this project we want to see if we can use the same test on a patient's blood sample, rather than a tissue sample. If successful, this will be less invasive for the patient, safer, more convenient, and will reduce the cost of the test.